ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 223 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $301 | -13.3% | 55,264 | +6.8% | 0.00% | 0.0% |
| Q2 2023 | $347 | -21.3% | 51,766 | +3.6% | 0.00% | 0.0% |
| Q1 2023 | $441 | +5.0% | 49,966 | -9.2% | 0.00% | 0.0% |
| Q4 2022 | $420 | -99.9% | 55,001 | +2.4% | 0.00% | 0.0% |
| Q3 2022 | $382,000 | -9.9% | 53,701 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $424,000 | -43.2% | 52,476 | -2.6% | 0.00% | -50.0% |
| Q1 2022 | $747,000 | -43.5% | 53,866 | +14.2% | 0.00% | -33.3% |
| Q4 2021 | $1,323,000 | -37.3% | 47,165 | -24.0% | 0.00% | -40.0% |
| Q3 2021 | $2,109,000 | -20.4% | 62,066 | -4.2% | 0.01% | -28.6% |
| Q2 2021 | $2,648,000 | +56.0% | 64,809 | +53.7% | 0.01% | +40.0% |
| Q1 2021 | $1,697,000 | -32.3% | 42,156 | -0.5% | 0.01% | -37.5% |
| Q4 2020 | $2,505,000 | +19.1% | 42,381 | -2.1% | 0.01% | +14.3% |
| Q3 2020 | $2,104,000 | +3.2% | 43,275 | +2.6% | 0.01% | -12.5% |
| Q2 2020 | $2,039,000 | +74.3% | 42,159 | +0.1% | 0.01% | +60.0% |
| Q1 2020 | $1,170,000 | – | 42,123 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |